A phase 1 study of JHL1188 (Trastuzumab biosimilar) to treat breast cancer.
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2018
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 22 Feb 2018 According to a JHL Biotech media release, European authority approved a Phase I Clinical Trial Application for JHL1149.
- 07 Feb 2018 New trial record
- 01 Feb 2018 According to a JHL Biotech media release, company plans to initiate this study in 2018.